Linker ID	LIN00062
Linker Name	4-(2-(glycylglycyl)hydrazineylidene)pentanoic acid
Linker Type	Enzyme-sensitive linkers
Structure
	2D MOL
Formula	C9H16N4O4
#Ro5 Violations (Lipinski): 0	Molecular Weight (mw)			244.251
	Lipid-water partition coefficient (xlogp)			-1.5818
	Hydrogen Bond Donor Count (hbonddonor)			4
	Hydrogen Bond Acceptor Count (hbondacc)			5
	Rotatable Bond Count (rotbonds)			7
Canonical smiles	CC(CCC(=O)O)=NNC(=O)CNC(=O)CN
InChI	InChI=1S/C9H16N4O4/c1-6(2-3-9(16)17)12-13-8(15)5-11-7(14)4-10/h2-5,10H2,1H3,(H,11,14)(H,13,15)(H,16,17)
InChIKey	NMCVDYCDYFFPHB-UHFFFAOYSA-N

Experiment 1 Reporting the Activity Data of This PDC					[1]
Indication	Metastatic Tumor
Efficacy Data	Median overall survival (mOS)	40.5 days
Administration Dosage	15 mg/kg PTX equivalent dose
Description	The median survival of mice in the P-(A5G27)-PTX treatment group was longer than in P-(A5G27scrm)-PTX, P-(A5G27), and free PTX-treated groups (48.50 vs 40.5, 43, and 45.5, respectively); however, differences were nonsignificant (Figure 6B).
In Vivo Model	4T1 tumor-bearing mice.

Experiment 1 Reporting the Activity Data of This PDC					[1]
Indication	Metastatic Tumor
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.221 ± 0.055 µM
Administration Time	72 h
Description	P-(A5G27)-PTX was ˜4-fold more toxic than the nontargeted P-(A5G27scrm)-PTX copolymer, suggesting a faster (receptor-mediated) internalization (Figure 4).
In Vitro Model	Mammary carcinoma	4T1 cell		CVCL_0125

Experiment 1 Reporting the Activity Data of This PDC					[1]
Indication	Metastatic Tumor
Efficacy Data	Median overall survival (mOS)	48.50 days
Administration Dosage	15 mg/kg PTX equivalent dose
Description	The median survival of mice in the P-(A5G27)-PTX treatment group was longer than in P-(A5G27scrm)-PTX, P-(A5G27), and free PTX-treated groups (48.50 vs 40.5, 43, and 45.5, respectively); however, differences were nonsignificant (Figure 6B).
In Vivo Model	4T1 tumor-bearing mice.

Experiment 1 Reporting the Activity Data of This PDC					[1]
Indication	Metastatic Tumor
Efficacy Data	Survival rate	40%
Administration Time	7 days
Administration Dosage	15 mg/kg PTX equivalent dose
Description	P-(A5G27)-PTX prolonged mice survival in 7 and 20% relative to the survival rates of free PTX and nontreated mice, respectively (Figure 5).
In Vivo Model	B16-F10 melanoma tumor-bearing mice model.

Experiment 1 Reporting the Activity Data of This PDC					[1]
Indication	Metastatic Tumor
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.058 ± 0.015 µM
Administration Time	72 h
Description	P-(A5G27)-PTX was ˜4-fold more toxic than the nontargeted P-(A5G27scrm)-PTX copolymer, suggesting a faster (receptor-mediated) internalization (Figure 4).
In Vitro Model	Mammary carcinoma	4T1 cell		CVCL_0125

Ref 1	CD44-Targeted Polymer-Paclitaxel Conjugates to Control the Spread and Growth of Metastatic Tumors. Mol Pharm. 2018 Sep 4;15(9):3690-3699. doi: 10.1021/acs.molpharmaceut.8b00269. Epub 2018 Jun 29.